scholarly article | Q13442814 |
P50 | author | Masahiro Kawahara | Q66829145 |
P2093 | author name string | Atsushi Kumanogoh | |
Tatsuaki Tsuruyama | |||
Hironori Haga | |||
Chiyuki Ueshima | |||
Masahiro Hirata | |||
Tatsuki R Kataoka | |||
Koki Moriyoshi | |||
P2860 | cites work | CD72 negatively regulates KIT-mediated responses in human mast cells | Q24297400 |
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors | Q28118852 | ||
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling | Q28140151 | ||
Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses | Q28189775 | ||
Stat4 suppresses the proliferation of connective tissue-type mast cells. | Q53473580 | ||
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias | Q59511707 | ||
c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia | Q59511748 | ||
Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias | Q67544291 | ||
Kit as a human oncogenic tyrosine kinase | Q28297098 | ||
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia | Q28300267 | ||
Identification of CD72 as a Lymphocyte Receptor for the Class IV Semaphorin CD100 | Q29036802 | ||
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder | Q33784323 | ||
The CD100-CD72 interaction: a novel mechanism of immune regulation | Q34460685 | ||
A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail | Q36220787 | ||
Integrated signalling pathways for mast-cell activation | Q36392833 | ||
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders | Q36842503 | ||
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications | Q37208315 | ||
Immunotherapy prospects for acute myeloid leukaemia | Q37763280 | ||
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product | Q38315689 | ||
CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes | Q39133323 | ||
Casticin induces leukemic cell death through apoptosis and mitotic catastrophe | Q39896019 | ||
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells | Q40077017 | ||
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. | Q40140332 | ||
The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells | Q40217567 | ||
Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. | Q40266774 | ||
STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade | Q40418498 | ||
KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. | Q40477263 | ||
CD72 stimulation modulates anti-IgM induced apoptotic signaling through the pathway of NF-kappaB, c-Myc and p27(Kip1). | Q40597201 | ||
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells | Q40627348 | ||
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia | Q40719234 | ||
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations | Q40748765 | ||
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. | Q40869447 | ||
The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. | Q41008340 | ||
The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. | Q41042524 | ||
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. | Q41685189 | ||
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit | Q44539087 | ||
CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function | Q46208076 | ||
Familial gastrointestinal stromal tumours with germline mutation of the KIT gene | Q47714133 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
cell line | Q21014462 | ||
P304 | page(s) | 2861 | |
P577 | publication date | 2013-10-04 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1. | |
P478 | volume | 3 |
Q36489379 | Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells |
Q38778743 | Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways. |
Q41043876 | Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis |
Q64260508 | Semaphorins and Their Receptors in Hematological Malignancies |
Q55405777 | The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis. |
Search more.